Prof. Dr. Meral Beksaç

HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma

Chemical Biology and Drug Design, 2023

DOI 10.1111/cbdd.14237 PMID 37094820 13 atıf (Europe PMC) Kaynak: ORCID

Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study

European Journal of Haematology, 2023

DOI 10.1111/ejh.13981 PMID 37082839 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

Research Square, 2023

DOI 10.21203/rs.3.rs-3325630/v1 Açık erişimli tam metinKaynak: ORCID

Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis

Clinical Lymphoma Myeloma and Leukemia, 2023

Kaynak: ORCID

Isatuximab–pomalidomide–dexamethasone vs. pomalidomide–dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

Research Square, 2023

DOI 10.21203/rs.3.rs-3117230 Kaynak: ORCID

Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: final overall survival analysis from the TOURMALINE-MM4 study

Clinical Lymphoma Myeloma and Leukemia, 2023

Kaynak: ORCID

LONG TERM OUTCOMES FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN DEPOSITION DISEASE: A RETROSPECTIVE STUDY ON BEHALF OF THE CMWP OF THE EBMT

Bone Marrow Transplantation, 2023

Kaynak: ORCID

Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

Blood, 2023

DOI 10.1182/blood-2023-184367 Kaynak: ORCID

MajesTEC-4: Phase 3 trial of Teclistamab plus Lenalidomide versus Lenalidomide in patients with newly diagnosed multiple myeloma

British Journal of Haematology, 2023

Kaynak: ORCID

Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

The Lancet Oncology, 2023

DOI 10.1016/s1470-2045(23)00223-1 PMID 37414019 115 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.21.02734 PMID 36413710 111 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Phase 3 Randomized Study of Daratumumab (DARA) plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Blood, 2023

Kaynak: ORCID

Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial

Clinical Lymphoma Myeloma and Leukemia, 2023

Kaynak: ORCID

Post-induction undetectable flow minimal residual disease ameliorates the high risk determined by FISH among newly diagnosed multiple myeloma

Clinical Lymphoma Myeloma and Leukemia, 2023

Kaynak: ORCID

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

The Lancet Oncology, 2023

DOI 10.1016/s1470-2045(23)00159-6 PMID 37269857 170 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT

Bone Marrow Transplantation, 2023

DOI 10.1038/s41409-023-01915-7 PMID 36681775 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation

Journal of Clinical Apheresis, 2023

DOI 10.1002/jca.22079 PMID 37503703 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

The Lancet Haematology, 2023

DOI 10.1016/s2352-3026(23)00218-1 PMID 37793772 36 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

Journal of Oncology Pharmacy Practice, 2023

DOI 10.1177/10781552221103551 PMID 36067063 14 atıf (Europe PMC) Kaynak: ORCID

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve LongTerm Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

Blood, 2023

DOI 10.1182/blood-2023-178533 4 atıf (OpenAlex) Kaynak: ORCID

Upfront autologous transplantation still improving outcomes in patients with multiple myeloma

The Lancet Haematology, 2023

DOI 10.1016/s2352-3026(22)00360-x PMID 36529146 11 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Validation of two international myeloma staging systems: second revision of ISS and mayo additive staging sytems (MASS) in an external cohort of Ankara University

Clinical Lymphoma Myeloma and Leukemia, 2023

Kaynak: ORCID

Werner helicase is required for proliferation and DNA damage repair in multiple myeloma

Molecular Biology Reports, 2023

DOI 10.1007/s11033-022-08178-3 PMID 36515823 3 atıf (Europe PMC) Kaynak: ORCID

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Blood, 2023

DOI 10.1182/blood-2023-191911 18 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)

HemaSphere, 2023

DOI 10.1097/01.hs9.0000970392.99459.3a 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

P956: VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN A REAL WORLD COHORT: AN ANALYSIS BY THE BALKAN MYELOMA STUDY GROUP (BMSG)

HemaSphere, 2023

DOI 10.1097/01.hs9.0000970728.42006.4a 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

P15 VALIDATION OF THE NOVEL EUROPEAN MYELOMA NETWORK PROGNOSTIC SCORE (R2-ISS) IN AN INDEPENDENT REAL-WORLD SETTING

HemaSphere, 2023

DOI 10.1097/01.hs9.0000936188.13446.94 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES

HemaSphere, 2023

DOI 10.1097/01.hs9.0000970776.33983.01 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Trends in AL Amyloidosis: Decrease in Early Mortality, Increase in Survival but Less AHCT: Single Center Experience

Transplantation and Cellular Therapy, 2023

DOI 10.1016/s2666-6367(23)00605-x Açık erişimli tam metinKaynak: OpenAlex

P05 ACETYL SALICYLIC ACID INDUCES POLARIZATION OF MACROPHAGES AND CYTOTOXICITY ON MYELOMA CELLS IN VITRO

HemaSphere, 2023

DOI 10.1097/01.hs9.0000936148.23905.0b Açık erişimli tam metinKaynak: OpenAlex

PB2213: RETROSPECTIVE ANALYSIS OF 45 UNSELECTED PATIENTS WITH HISTIOCYTOSIS CONFIRMS PROGNOSTIC RELEVANCE OF ORGAN INVOLVEMENT: SINGLE‐CENTER EXPERIENCE

HemaSphere, 2023

DOI 10.1097/01.hs9.0000975600.58393.5d Açık erişimli tam metinKaynak: OpenAlex

POSTER: MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis

Clinical Lymphoma Myeloma & Leukemia, 2023

DOI 10.1016/s2152-2650(23)00810-8 Kaynak: OpenAlex

POSTER: MM-182 Allocation and Validation of the Second Revision of the International Staging System in the ICARIA-MM and IKEMA Studies

Clinical Lymphoma Myeloma & Leukemia, 2023

DOI 10.1016/s2152-2650(23)00806-6 Açık erişimli tam metinKaynak: OpenAlex

MM-182 Allocation and Validation of the Second Revision of the International Staging System in the ICARIA-MM and IKEMA Studies

Clinical Lymphoma Myeloma & Leukemia, 2023

DOI 10.1016/s2152-2650(23)01414-3 Kaynak: OpenAlex

MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis

Clinical Lymphoma Myeloma & Leukemia, 2023

DOI 10.1016/s2152-2650(23)01424-6 Kaynak: OpenAlex

P-110 Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: final overall survival analysis from the TOURMALINE-MM4 study

Clinical Lymphoma Myeloma & Leukemia, 2023

DOI 10.1016/s2152-2650(23)01728-7 Kaynak: OpenAlex

P-133 Validation of two international myeloma staging systems: second revision of ISS and mayo additive staging sytems (MASS) in an external cohort of Ankara University

Clinical Lymphoma Myeloma & Leukemia, 2023

DOI 10.1016/s2152-2650(23)01751-2 Kaynak: OpenAlex

P-278: Post-authorization safety of lenalidomide + dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey

Clinical Lymphoma Myeloma & Leukemia, 2022

DOI 10.1016/s2152-2650(22)00608-5 Kaynak: OpenAlex

Ex Vivo Epigenetic Modification with Valproic Acid (VPA) Plus Nicotinamide (NAM) Results in Expansion of Umbilical Cord Blood Hematopoietic Progenitors Leading to Faster Engraftment and Chimerism in In Vivo Mouse Xenograft Model

Transplantation and Cellular Therapy, 2022

DOI 10.1016/s2666-6367(22)00596-6 Açık erişimli tam metinKaynak: OpenAlex

PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA

HemaSphere, 2022

DOI 10.1097/01.hs9.0000851128.52895.ec 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

Transplantation and Cellular Therapy, 2022

DOI 10.1016/j.jtct.2022.03.019 PMID 35306217 27 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

The Lancet Haematology, 2022

DOI 10.1016/s2352-3026(22)00226-5 PMID 36174641 37 atıf (Europe PMC) Kaynak: ORCID

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

The Lancet Haematology, 2022

DOI 10.1016/s2352-3026(22)00103-x PMID 35550060 41 atıf (Europe PMC) Kaynak: ORCID

Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience

Bone Marrow Transplantation, 2022

Kaynak: ORCID

Are Generic Imatinib Formulations Really as Effective as Originial Imatinib in Chronic Myeloid Leukemia: Real Life Data

Research Square, 2022

DOI 10.21203/rs.3.rs-2316364/v1 Açık erişimli tam metinKaynak: ORCID

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Blood, 2022

DOI 10.1182/blood-2022-169736 Kaynak: ORCID

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT

Bone Marrow Transplantation, 2022

DOI 10.1038/s41409-022-01592-y PMID 35169284 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

The Lancet Oncology, 2022

DOI 10.1016/s1470-2045(21)00579-9 PMID 34871550 141 atıf (Europe PMC) Kaynak: ORCID

Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma

Clinical Lymphoma Myeloma and Leukemia, 2022

Kaynak: ORCID

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Bone Marrow Transplantation, 2022

DOI 10.1038/s41409-021-01560-y PMID 35013536 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID